The infectious disease drug developer has applied to float in Hong Kong, which will enable the WuXi AppTec-backed 6 Dimensions Capital to exit.

Brii Biosciences, a China-based chronic disease therapy developer backed by pharmaceutical group WuXi AppTec, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange.

The offering’s lead underwriters are Morgan Stanley Asia and UBS Hong Kong. Although its size and timeline are not yet disclosed, Bloomberg reported in August 2020 the company intended to raise up to $400m when it floated.

Brii Bio is working on drugs intended to treat illnesses that do not have…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn